PANoptosis and mitochondrial regulatory mechanisms in cerebral ischemia-reperfusion injury

TL;DR

This paper explores how brain cells die during stroke recovery by combining multiple death pathways, suggesting new treatment strategies targeting mitochondria.

Contribution

The paper introduces the concept of PANoptosis in cerebral ischemia-reperfusion injury, highlighting mitochondrial dysfunction as a central mechanism.

Findings

Mitochondrial dysfunction acts as a central hub for activating multiple cell death pathways during cerebral ischemia-reperfusion.

Pharmacological targeting of single pathways is insufficient due to pathway redundancy and simultaneous activation.

Multi-pathway cell death features are observed in neurons, astrocytes, microglia, and endothelial cells.

Abstract

Cerebral ischemia-reperfusion injury remains a leading cause of mortality and disability despite advances in reperfusion therapy. Traditional research has focused on individual cell death pathways, yet pharmacological blockade of single pathways provides only partial neuroprotection, suggesting that dying cells engage multiple death routes simultaneously. This review examines whether PANoptosis, an inflammatory cell death modality characterized by concurrent activation of apoptotic, necroptotic, and pyroptotic pathways, occurs in cerebral ischemia-reperfusion injury. The analysis demonstrates that mitochondrial dysfunction serves as the central convergence point orchestrating multi-pathway death activation across distinct temporal phases. Ischemia creates metabolic crisis that primes mitochondria without triggering irreversible commitment. Reperfusion causes explosive mitochondrial collapse through oxidative stress, releasing danger signals that simultaneously engage multiple death pathways. Impaired mitochondrial quality control then sustains inflammatory amplification over extended periods. Multiple lines of evidence support this framework, including concurrent rather than sequential appearance of pathway markers, mixed morphological features within individual cells, pathway redundancy demonstrated by incomplete single-target protection, and mechanistic convergence at the mitochondrial level. Cellular responses vary among neurons, astrocytes, microglia, and endothelial cells but share the common feature of coordinated multi-pathway activation. This integrated understanding explains why single-pathway therapeutic approaches have failed clinically and suggests that effective neuroprotection requires targeting upstream mitochondrial dysfunction or addressing pathway redundancy through multi-target interventions.

Figures